To date, several small molecule inhibitors and monoclonal-antibodies (like 
ICR-62) have been used to treat tumors over-expressing epidermal growth factor 
receptor (EGFR). However, the limitations associated with these conventional 
applications accentuate the necessity of alternative approaches. Mimotopes as 
compelling molecular tools could rationally be employed to circumvent these 
drawbacks. In the present study, an M13 phage displaying ICR-62 binding peptide 
mimotope is exploited as a vaccine candidate. It exhibited high affinity towards 
ICR62 and polyclonal anti-P-BSA antibodies. Following the mice immunization, 
phage-based mimotope vaccine induced humoral immunity. Elicited anti-EGFR 
mimotope antibodies were detected using ELISA method. Moreover, the phage 
vaccine was tested on the Lewis lung carcinoma mice model to investigate the 
prophylactic and therapeutic effects. The tumor volume was measured and recorded 
in different animal groups to evaluate the anti-tumor effects of the vaccine. 
Our data indicate that the reported phage-based mimotope could potentially 
elicit specific antibodies resulting in low titers of EGFR-specific antibodies 
and reduced tumor growth. However, in vivo experiments of prophylactic or 
therapeutic vaccination showed no specific advantage. Furthermore, 
phage-mimotope vaccine might be a promising approach in the field of cancer 
immunotherapy.